Cardiac markers represent one of Hytest’s main clinical focus areas, developed through years of research and supported by robust scientific evidence. We are proud to announce the addition of a new cardiac marker product—recombinant Growth Differentiation Factor 15 (GDF15) antigen (Cat. #8DF5)—to complement our existing portfolio.

GDF15, a cytokine belonging to the transforming growth factor-beta (TGF-β) superfamily, is upregulated in a variety of pathological conditions, including oxidative stress, endothelial dysfunction, tissue aging, and chronic inflammation. Abnormal GDF15 levels have been linked to several important disease areas including,

· Cancer – both as a diagnostic biomarker and as a prognosticator of tumor development and progression.

· Cardiovascular diseases – such as acute myocardial infarction (AMI) and cardiac hypertrophy, where it serves as both a diagnostic and prognostic biomarker.

· Inflammation suppression – reflecting chronic and acute inflammatory responses.

· Metabolic diseases – such as obesity, anorexia, and cachexia, where GDF15 is associated with metabolic and systemic stress.

Among these diverse applications, GDF15 is particularly valuable in cardiovascular diseases. Several international guidelines highlight its importance, including the 2020 European Society of Cardiology (ESC) Guidelines for atrial fibrillation, developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). This guideline recommends GDF15 for stroke risk assessment alongside other biomarkers. In addition, GDF15—together with Cystatin C/CKD-EPI, cTnT-hs, and von Willebrand factor—is recommended for bleeding risk assessment. In summary, immunoassays for the quantitative determination of GDF15 in human serum and plasma are strongly associated with cardiovascular risk prediction, recurrent myocardial infarction and bleeding risk, heart failure prognosis, and atrial fibrillation-related bleeding risk assessment.

At Hytest, we pride ourselves on being a research- and science-driven raw material company, consistently staying at the forefront of innovation. We are committed to identifying and developing cutting-edge, emerging biomarkers that shape the future of diagnostics and precision medicine.

With the launch of Cat. #8DF5, Hytest further strengthens its position as a leading supplier in the cardiovascular biomarker segment, meeting customer demand for comprehensive and reliable biomarker solutions. Cat. #8DF5 can be used as a calibrator or control in the development of GDF15 immunoassays, offering >95% purity, excellent lot-to-lot consistency, and scalable production—ensuring a secure and reliable supply for assay development.

New GDF15 antibody products will also be available soon—stay tuned. For ordering or additional technical information, please contact our Sales Team or visit our website.

More Information:

Cat. # 8DF5 Growth differentiation factor 15 (GDF15) Datasheet